EPISODE · Jul 22, 2025 · 17 MIN
Metsera CEO Whit Bernard shares an update on the company's obesity programs, and comments on the state of the field post ADA
from BiotechTV - News · host BiotechTV
He describes data that Mestera presented at ADA for its monthly-dosed GLP1 and also its amylin analog. Plus, recent learnings about the field in general, including what orforglipron might mean for the oral therapy space and why Metsera believes in an oral peptide.
What this episode covers
He describes data that Mestera presented at ADA for its monthly-dosed GLP1 and also its amylin analog. Plus, recent learnings about the field in general, including what orforglipron might mean for the oral therapy space and why Metsera believes in an oral peptide.
NOW PLAYING
Metsera CEO Whit Bernard shares an update on the company's obesity programs, and comments on the state of the field post ADA
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m